COMMUNITY ACOUIRED PNEUMONIA GUIDELINES (Part 1 of 3)

SITE-OF-CARE DECISIONS

- Determine if patient should be treated inpatient or outpatient
 - Outpatient care: able to take oral medications and have adequate outpatient care
 - Inpatient care: based on severity-of-illness scores (eq, CURB-65 criteria [confusion, uremia, respiratory rate, low blood pressure, 65 years or older]) or prognostic models (eq, Pneumonia Severity Index [PSI]) and professional judgment
- Patients with CURB-65 score ≥2 require hospitalization or aggressive outpatient care
- If inpatient treatment required, determine if patient should be admitted to ICU or general ward ICU admission required: septic shock necessitating vasopressors, or acute respiratory failure requiring intubation and mechanical ventilation
 - ICU admission recommended: 1 major criteria or 3 minor criteria are present

SEVERE CAP CRITERIA

Minor Criteria:

- Hypothermia (<36°C) PaO₂/FiO₂ ratio ≤250
- Uremia (BUN ≥20mg/dL)
- Thrombocytopenia (platelets <100000 cells/mm³)
- Leukopenia (WBC <4000 cells/mm³)
 Hypotension requiring aggressive fluid resuscitation
- Multilobar infiltrates
- Other considerations: hypoglycemia, acute alcoholism/alcoholic withdrawal, hyponatremia, unexplained metabolic acidosis, elevated lactate, cirrhosis, asplenia
- Confusion/disorientation
- Respiratory rate ≥30 breaths/min

Maior Criteria

- Invasive mechanical ventilation
- Septic shock requiring vasopressors

DIAGNOSTIC TESTS

Physical exam:

- Crackles or rales, bronchial breath sounds, hypoxemia, tachypnic
- Signs/symptoms of cough, fever, sputum production, pleuritic chest pain

Chest radiograph:

- Observe apparent lobar or bilateral infiltrates with or without microbiological evidence
- · Hospitalized for suspected pneumonia but negative chest radiograph: may receive empiric antibiotics with repeat chest radiograph 24-48hrs later
- Lab tests:
 - Pretreatment blood culture and/or expectorated sputum samples for culture and gram stain should be taken if: ICU admission, outpatient antibiotic therapy failure, cavitary infiltrates, leukopenia, active alcohol abuse, chronic severe liver and lung disease, asplenia, positive Legionella or pneumococcal UAT result, pleural effusion; optional for other indications Tests mentioned above are optional in patients without these conditions
- Pulse oximetry
- Severe CAP: should obtain blood culture, expectorated sputum culture, urinary antigen tests for Legionella pneumophila and S. pneumoniae; endotracheal aspirate sample for intubated patients
- Nonresponsive to antibiotics: chest CT. thoracentesis, bronchoscopy with BAL and transbronchial biopsies to rule out other reasons for antibiotic failure
- Diagnostic tests to determine etiology are optional for outpatients

OUTPATIENT EMPIRICAL TREATMENT

Previously healthy with no risk factors for drug-resistant <i>S. pneumoniae</i> (DRSP) infection or no use of antimicrobials within previous 3 months	Macrolide: • azithromycin, clarithromycin, or erythromycin Alternative: doxycycline
Comorbid conditions: Diabetes, chronic heart, lung, liver, or renal disease, alcoholism, malignancies, asplenia, immunosuppressive conditions or drugs, use of antimicrobials in the previous 3 months, or other risks for DRSP infection	Respiratory Fluoroquinolone: • moxifloxacin, gemifloxacin, or levofloxacin (750mg) OR β-Lactam PLUS Macrolide: • amoxicillin (1g three times daily) or • amoxicillin/clavulanate (2g twice daily) or • cefpodoxime, ceftriaxone, or cefuroxime (500mg twice daily) plus • azithromycin, clarithromycin, or erythromycin Alternative to the Macrolide: doxycycline
Regions with high rate (>25%) of macrolide-resistant <i>S. pneumoniae</i>	Consider alternative agents: • eg, β-Lactam or Respiratory Fluoroquinolone

COMMUNITY ACQUIRED PNEUMONIA GUIDELINES (Part 2 of 3)

INPATIENT EMPIRICAL TREATMENT		
Non-ICU		
Recommendations:	Respiratory Fluoroquinolone OR	
	β-Lactam PLUS Macrolide: • cefotaxime, ceftriaxone, or ampicillin plus • ertapenem (selected patients)	
	Alternative to the Macrolide: doxycycline **Penicillin Allergy**: use Respiratory Fluoroquinolone	
ICU		
Minimal Recommendations:	 β-Lactam PLUS Azithromycin OR Fluoroquinolone: cefotaxime, ceftriaxone, ampicillin/sulbactam **Penicillin Allergy*: a Respiratory Fluoroquinolone AND Aztreonam are recommended 	
Additional Recommendations or Modifications: If Pseudomonas Infection	Antipneumococcal Antipseudomonal β-Lactam* PLUS Ciprofloxacin OR Levofloxacin (750mg): • piperacillin-tazobactam, cefepime, imipenem, meropenem OR *Above β-Lactam PLUS Aminoglycoside AND Azithromycin OR *Above β-Lactam PLUS Aminoglycoside AND Antipneumococcal Fluoroquinolone	
If Community-Acquired Methicillin- Resistant S. aureus (CA-MRSA)	Add vancomycin or linezolid	
PATHOGEN SPECIFIC TREATM	ENT	
<i>S. pneumoniae</i> PCN susceptible (MIC <2µg/mL)	Preferred: penicillin G, amoxicillin Alternative: macrolide, cephalosporins (cefpodoxime, cefprozil, cefuroxime, cefdinir, ceftriaxone, cefotaxime), clindamycin, doxycycline, respiratory fluoroquinolone	
<i>S. pneumoniae</i> PCN resistant (MIC ≥2µg/mL)	Preferred: based on susceptibility including cefotaxime, ceftriaxone, fluroquinolone Alternative: vancomycin, linezolid, high-dose amoxicillin (3g/day with PCN MIC ≤4µg/mL)	
<i>H. influenzae</i> non-β-lactamase producing	Preferred: amoxicillin Alternative: fluoroquinolone, doxycycline, azithromycin, clarithromycin	
<i>H. influenzae</i> β -lactamase producing	Preferred: 2nd or 3rd generation cephalosporin, amoxicillin/clavulanate Alternative: fluoroquinolone, doxycycline, azithromycin, clarithromycin	
Legionella species	Preferred: fluoroquinolone, azithromycin Alternative: doxycycline	
Mycoplasma pneumoniae, Chlamydophila pneumoniae	Preferred: macrolide, tetracycline Alternative: fluoroquinolone	
Influenza A	Preferred: initiate oseltamivir or zanamivir within 48hrs if influenza A identified. Not recommended if uncomplicated influenza and symptoms ongoing for >48hrs.	
H5N1 Influenza	Preferred: oseltamivir 75mg twice daily for 5 days	
OTHER TREATMENTS		

- · Consider local resistance patterns, previous antibiotic use, and comorbidities when choosing empirical antibiotics
- Administer noninvasive ventilation in cases of hypoxemia or respiratory distress unless immediate intubation necessary due to severe hypoxemia or bilateral alveolar infiltrates
- Low-tidal-volume ventilation (6cm³/kg of IBW) for patients with diffuse bilateral pneumonia or acute respiratory distress syndrome
- Screen for occult adrenal insufficiency in hypotensive fluid-restricted patients with severe CAP

TREATMENT DURATION

- · Admission through Emergency department: administer 1st antibiotic dose in the ED
- Initiate treatment within 6–8hrs of presentation
- Duration: minimum 5 days of treatment, should be afebrile 48–72hrs, and no more than 1 CAP associated sign of clinical instability before discontinuing therapy
- Longer duration of therapy may be warranted in certain circumstances (eg, initial therapy did not target identified pathogen, extrapulmonary infections such as meningitis or endocarditis)

COMMUNITY ACQUIRED PNEUMONIA GUIDELINES (Part 3 of 3)

IV TO ORAL SWITCH

- Switch once hemodynamically stable, notable clinical improvement, normal functioning GI tract, and can ingest oral therapy
- Usually switch to oral form of same antibiotic or same pharmacological class
- Discharge once clinically stable, no other active medical problems, and have a safe environment for continued care as an outpatient

Criteria for Clinical Stability:

Temp ≤37.8°C

- Systolic blood pressure ≥90mmHg
- Heart rate ≤100 beats per min
 Arteri
- Respiratory rate ≤24 breaths per min
- Arterial O_2 saturation $\ge 90\%$ or $pO_2 \ge 60mmHg$
- Maintain oral intake and normal mental status

PREVENTION

- Smoking cessation should be advised in hospitalized patients
- Assess vaccination status at time of hospital admission
- Inactivated influenza vaccine recommended for all children 6–23 months and ≥50 years of age, high risk persons 6 months–49 years of age, household contacts of high-risk persons, healthcare workers, pregnancy, diabetes, asthma
- Pneumococcal vaccine recommended for persons ≥65 years of age, high-risk persons 2–64 years of age, smokers, diabetes, asplenia, alcoholism, chronic cardiovascular, pulmonary, renal, or liver disease
- Offer influenza vaccine administration during discharge or outpatient treatment; vaccines can be given during either time

REFERENCES

Mandell LA, Wunderink RG, Anzueto A, et. al. Infectious Disease Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. *IDSA/ATS*. 2007; 44 Suppl 2: S27–S63. (Rev. 11/2017)